Mydrane

Lidocaine Hydrochloride, Phenylephrine Hydrochloride, Tropicamide, the active ingredients in Mydrane, are a combination ophthalmic anesthetic and mydriatic presented as an intracameral solution for intra‑ocular use. It provides rapid pupil dilation and local anesthesia during cataract surgery and other intra‑ocular procedures.

GNH USA supplies Mydrane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Mydrane is used in ophthalmic surgery to achieve rapid mydriasis and anesthesia. - Cataract surgery: provides pupil dilation and analgesia facilitating lens removal. - Intra‑ocular lens implantation: ensures adequate pupil size and patient comfort during lens placement. - Other intra‑ocular procedures: enables rapid mydriasis and local anesthesia for procedures such as trabeculectomy or vitrectomy.

Mydrane may be associated with ocular and systemic adverse reactions following intracameral administration.

Common Side Effects: - Transient ocular pain: mild discomfort after injection. - Redness of the eye: temporary conjunctival hyperemia. - Increased intra‑ocular pressure: short‑term rise detectable post‑procedure. - Blurred vision: temporary visual disturbance. - Light sensitivity: photophobia lasting a few hours.

Serious or Rare Side Effects: - Allergic reaction: signs of hypersensitivity such as rash or swelling. - Persistent elevated intra‑ocular pressure: may require medical management. - Endophthalmitis: intra‑ocular infection, though rare. - Corneal edema: swelling affecting corneal clarity.

When using Mydrane, clinicians should consider several safety measures. - Patient assessment: evaluate for known hypersensitivity to lidocaine, phenylephrine, or tropicamide before use. - Cardiovascular status: use caution in patients with uncontrolled hypertension due to phenylephrine effects. - Ocular conditions: avoid in eyes with narrow-angle glaucoma or severe iris abnormalities. - Systemic disease: consider caution in patients with severe cardiac disease or arrhythmias. - Concomitant medications: review use of other mydriatics or adrenergic agents that may potentiate effects. - Store at ambient temperature: keep in original container, protect from light and moisture.

Mydrane can interact with other drugs, requiring attention to potential effects.

Major Interactions (Avoid): - Systemic phenylephrine: concurrent use may cause excessive vasoconstriction and hypertension. - Other topical mydriatics: combined use can lead to prolonged pupil dilation and increased intra‑ocular pressure. - MAO inhibitors: phenylephrine may potentiate hypertensive crisis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may attenuate phenylephrine‑induced pupil dilation. - Anticholinergic drugs: additive mydriatic effect when combined with tropicamide. - Local anesthetics: overlapping sodium channel blockade may increase anesthetic depth.